ASIT AIW ASIT biotech: Publishes the Documents Relating to the Ordinary General Shareholders' Meeting on 14 June 2018

Transparency directive : regulatory news

16/05/2018 17:45






Regulatory News:



ASIT biotech (Euronext: ASIT - BE0974289218) (Paris:ASIT) (BSE:ASIT),
a Belgian biopharmaceutical company specialized in allergy
immunotherapy, announces that shareholders are invited to attend the
Ordinary General Shareholders’ Meeting to be held on Thursday 14 June
2018 at 3.00 pm (CEST) at the ASIT biotech headquarters: 5 avenue Ariane
- 1200 Brussels, Belgium.



The documents are available upon request or can be consulted on the
Company’s website www.asitbiotech.com,
Investors section / General assembly.



***



About ASIT biotech

ASIT biotech is a Belgian clinical stage
biopharmaceutical company focused on the development and future
commercialization of a range of breakthrough immunotherapy products for
the treatment of allergies. Thanks to its innovative ASIT+™ technology
platform, ASIT biotech is currently the only developer of AIT product
candidates consisting of a unique mixture of highly purified natural
allergen fragments in an optimal size selection. This innovation results
in a short treatment, expected to improve patient compliance and
real-life effectiveness. ASIT biotech’s product pipeline entails two
novel ASIT+™ product candidates targeting respiratory allergy with the
highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite:
hdm-ASIT+™), that could significantly expand the current immunotherapy
market. The Company believes that its innovative ASIT+™ platform is
flexible and would be applicable across a range of allergies.



ASIT biotech has a headcount of 26 staff members, at its headquarters in
Brussels and a laboratory in Liège, Belgium.



Further information can be found at www.asitbiotech.com.



Forward-looking statements

All statements in this
announcement that do not relate to historical facts and events are
“forward-looking statements”. In some cases, these forward-looking
statements can be identified by the use of forward-looking terminology,
including the words “believes,” “estimates,” “anticipates,” “expects,”
“intends,” “may,” “will,” “plans,” “continue,” “ongoing,” “potential,”
“predict,” “project,” “target,” “seek” or “should” or, in each case,
their negative or other variations or comparable terminology or by
discussions of strategies, plans, objectives, targets, goals, future
events or intentions. Forward-looking statements include statements
regarding the Company’s intentions, beliefs or current expectations. By
their nature, forward-looking statements involve known and unknown risks
and uncertainties because they relate to events and depend on
circumstances that may or may not occur in the future. Forward-looking
statements are not guarantees of future performance. Given these risks
and uncertainties, you should not rely on forward-looking statements as
a prediction of actual results. Any forward-looking statements are made
only as of the date of this announcement and, without prejudice to the
Company’s obligations under applicable law in relation to disclosure and
ongoing information, the Company does not intend, and does not assume
any obligation, to update the forward-looking statements set forth in
this announcement.



Legal notice

This announcement does not constitute, or form
part of, an offer or invitation to sell or issue, or any solicitation of
an offer to purchase or subscribe for shares of ASIT biotech SA (the
“Company” and the “Shares”). Any purchase of, subscription for or
application for, Shares to be issued in connection with the intended
offering should only be made on the basis of information contained in
the prospectus and any supplements thereto, as the case may be. This
announcement does not constitute a prospectus and the information
contained herein is for information purposes only and does not purport
to be full or complete. Investors should not subscribe for any Shares
except on the basis of the information contained in the prospectus that
the Company expects to publish after its approval by the Belgian
Financial Services and Markets Authority, and which can then be obtained
at the Company’s registered office and on www.asitbiotech.com



This announcement is not for distribution, directly or indirectly, in or
into the United States or to any U.S. person within the meaning of the
U.S. Securities Act of 1933, as amended (the “Securities Act”). The
Shares have not been and will not be registered under the Securities Act
and may not be offered or sold in the United States, except pursuant to
an exemption from the registration requirements of the Securities Act.
The Company has not registered, and does not intend to register, any
portion of the intended offering of Shares in the United States, and
does not intend to conduct a public offering of Shares in the United
States.



This announcement and the information contained herein are not for
publication, distribution or release in or into the United States,
Australia, Canada, Japan or any jurisdiction where to do so would
constitute a violation of the relevant laws of such jurisdiction.



The Company is responsible for the information contained in this press
release.








ASIT biotech

Thierry Legon, Tel.: +32 2 264 03 90
CEO
ASIT
biotech

investors@asitbiotech.com

or

Media
and Investor Relations - France


NewCap
Dusan Oresansky /
Pierre Laurent, Tel.: +33 1 44 71 94 92

asitbiotech@newcap.eu

or

Media
Relations - Belgium


Laure-Eve Monfort, Tel.: +32 2 290 90 93

monfort@comfi.be